Vertex Pharmaceuticals Incorporated

VRTX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.2%

Institutions98.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$12.00B	$11.02B	$9.87B	$8.93B	$7.57B	$6.21B	$4.16B	$3.05B	$2.49B	$1.70B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$1.65B	$1.53B	$1.26B	$1.08B	$904.20M	$736.30M	$547.76M	$409.54M	$272.68M	$206.81M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$4.17B	-$232.90M	$3.83B	$4.31B	$2.78B	$2.86B	$1.20B	$635.15M	$123.24M	$9.94M
Operating income as a percentage of revenue.	34.8%	-2.1%	38.8%	48.2%	36.7%	46.0%	28.8%	20.8%	5.0%	0.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$3.95B	-$535.60M	$3.62B	$3.32B	$2.34B	$0	$0	$2.10B	$263.48M	-$112.05M
Net income divided by the number of shares outstanding — profit attributable to each share.	$15.46	$-2.08	$14.05	$12.97	$9.09	$10.44	$4.58	$8.00	$1.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$15.32	$-2.08	$13.89	$12.82	$9.01	$10.29	$4.51	$8.00	$1.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$5.08B	$4.57B	$10.37B	$10.50B	$6.79B	$5.99B	$3.11B	$2.65B	$1.67B	$1.18B
Everything the company owns that has value — cash, property, inventory, investments, and more.	$25.64B	$22.53B	$22.73B	$18.15B	$13.43B	$11.75B	$8.32B	$6.25B	$3.55B	$2.90B
Everything the company owes — debt, unpaid bills, and other obligations.	$6.98B	$6.12B	$5.15B	$4.24B	$3.33B	$3.06B	$2.23B	$1.81B	$1.50B	$1.56B
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$18.67B	$16.41B	$17.58B	$13.91B	$10.10B	$8.69B	$6.09B	$4.44B	$2.03B	$1.16B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$3.63B	-$492.60M	$3.54B	$4.13B	$2.64B	$3.25B	$1.57B	$1.27B	$844.94M	$236.10M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$437.60M	$297.70M	$200.40M	$204.70M	$235.00M	$259.80M	$75.45M	$95.52M	$99.42M	$56.56M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$3.19B	-$790.30M	$3.34B	$3.93B	$2.41B	$2.99B	$1.49B	$1.17B	$745.52M	$179.54M

	You	Peer avg
P/E	30.8	47.8
Revenue Growth	+12.5%	+2284.6%
ROE	23.5%	-10.2%

Vertex Pharmaceuticals Incorporated

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison